4-methyl-7-hydroxy-8-phthalimidomethylquinolino[1,2-a]benzimidazole | 477808-80-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: 4-methyl-7-hydroxy-8-phthalimidomethylquinolino[1,2-a]benzimidazole
• CAS: 477808-80-3
• 化学式: C₂₅H₁₇N₃O₃
• 分子量: 407.428
• InChiKey: PUVQSCREZMXTQC-UHFFFAOYSA-N

物化性质

• 熔点：
  101 °C
• 密度：
  1.45±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.45
• 重原子数：
  31.0
• 可旋转键数：
  2.0
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  74.91
• 氢给体数：
  1.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  4-methyl-7-hydroxy-8-phthalimidomethylquinolino[1,2-a]benzimidazole 、 对甲基苯甲醛 在 溶剂黄146 作用下， 生成
  参考文献：
  名称：

  Synthesis, Analytical Analysis, and Medicinal Aspect of Novel Benzimidazoles and their Metal Complexes

  摘要：

  Benzimidazole and their metal analogs that can act as multimodal agent and have non‐peptidic CCK‐B receptor antagonist were synthesized and characterized on the basis of spectroscopic techniques such as FT‐IR, NMR, FAB‐MS and also evaluated for biologic efficacy. The ligands showed binding to most of the organs, known to express CCK receptors in biodistribution studies. Cholecystokinin (CCK1 and CCK2) receptor binding affinities of these analogs (IC50) are 0.802 ± 0.007 for compound C and 0.326 ± 0.012 for compound D in rat pancreatic acini. These studies have provided a new template for further development of novel agents for various related diseases.

  DOI：

  10.1111/cbdd.12201
• 作为产物：
  描述：

  N-羟甲基邻苯二甲酰亚胺 在 吡啶 、 硫酸 作用下， 反应 7.0h， 生成 4-methyl-7-hydroxy-8-phthalimidomethylquinolino[1,2-a]benzimidazole
  参考文献：
  名称：

  Synthesis, Analytical Analysis, and Medicinal Aspect of Novel Benzimidazoles and their Metal Complexes

  摘要：

  Benzimidazole and their metal analogs that can act as multimodal agent and have non‐peptidic CCK‐B receptor antagonist were synthesized and characterized on the basis of spectroscopic techniques such as FT‐IR, NMR, FAB‐MS and also evaluated for biologic efficacy. The ligands showed binding to most of the organs, known to express CCK receptors in biodistribution studies. Cholecystokinin (CCK1 and CCK2) receptor binding affinities of these analogs (IC50) are 0.802 ± 0.007 for compound C and 0.326 ± 0.012 for compound D in rat pancreatic acini. These studies have provided a new template for further development of novel agents for various related diseases.

  DOI：

  10.1111/cbdd.12201

文献信息

• Synthesis and evaluation of Novel Benzimidazole derivative [Bz-Im] and its radio/biological studies
  作者：Anjani K. Tiwari、Anil K. Mishra、Aruna Bajpai、Pushpa Mishra、Sweta Singh、Deepa Sinha、V.K. Singh

  DOI：10.1016/j.bmcl.2007.02.071

  日期：2007.5

  Two different benzimidazole analogues act as multimodal agent, first one as novel non-peptidic CCK-B receptor antagonist and similarly as potent anti-fungal agent, designated as [Bz-Im]. These compounds were synthesized and characterized by spectroscopic techniques such as FT-IR, NMR, El-MS and also evaluated for specific radiopharmaceuticals. Preliminary radiolabeling results with Tc-99m and biological evaluation studies showed promising results for further evaluation in vivo. The efficiency of labeling was more than 97% and complex was stable for about 12 h at 30 degrees C in the presence of serum. Both ligands showed binding to most of the organs, known to express CCK receptors in biodistribution studies. Cholecystokinin (CCK, andCCK(2)) receptor binding affinities of these analogues are, IC50, 0.942 +/- 0.107 for compound C and 0.665 +/- 0.211 for compound D in rat pancreatic acini. The anti-fungal activity has shown inhibitory activity against Aspergillus flavus and Aspergillus niger. These studies have provided a new template for further development of non-peptidic ligands for diagnostic and therapeutic purposes of diseases related with CCK receptors as well as anti-microbes. (c) 2007 Elsevier Ltd. All rights reserved.